David Grainger Explained

David Grainger
Caption:Partner at Index Ventures, blogger
Alma Mater:Cambridge University
Birth Date:12 October 1966
Occupation:venture capitalist, medicxi, biotechnology executive, Methuselah Health Ltd., blogger

David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm[1] and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space.[2] [3]

He was formerly with Index Ventures, an international venture capital firm with offices in London, Geneva and San Francisco,[4] in the firm's life sciences practice. He also writes for Forbes.com on topics related to the pharmaceutical industry.[5]

Education

Reared in England, Grainger graduated with degree in Natural Sciences (Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992.[6]

Career

After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University.[7] Following publications in Nature[8] and elsewhere[9] setting out his Protective Cytokine Hypothesis explaining the role of the cytokine TGF-beta 1 in the cardiovascular system,[10] Grainger was appointed principal investigator in the Department of Medicine at his alma mater, Cambridge University, in 1997.[11]

While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001),[12] and Funxional Therapeutics (2005).[13] FingerPrint Diagnostics merged with SmartBead Technologies to form Pronostics, a molecular diagnostics company, in 2006.[14] Funxional Therapeutics, based on an anti-inflammatory drug candidate spun-out from Grainger's Cambridge University lab, became an Index Ventures portfolio company where Grainger also served as chief scientific officer until it was sold to Boehringer Ingelheim in 2012.[15]

Grainger joined Index Ventures in 2012,[16] and a blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”.[17] where he was involved with funding and advising a variety of companies, including XO1,[18] a biotech company developing an anticoagulant, where he served as chairman and interim CEO before it was sold to Johnson & Johnson[19] [20] [21] He co-founded medicxi in February 2016 with fellow former Index Ventures partners Francesco De Rubertis, Kevin Johnson and Michele Ollier.[1] [22]

Publications and Patents

Grainger has co-authored a number of papers in peer-reviewed scientific journals,[23] including Nature, Science[24] and Nature Medicine.[25] Grainger formerly blogged under the pen name “DrugBaron” on a range of topics related to the pharmaceutical industry,[26] and now has a column on similar topics on Forbes.com.

External links

Notes and References

  1. News: Backed by J&J and Glaxo, veteran VC group splits from Index, unveils $227M fund . FierceBiotech . February 1, 2016.
  2. News: Methuselah Health CEO David Grainger is out to aid longevity. FierceCEO. January 4, 2018. 2 March 2018. 3 March 2018. https://web.archive.org/web/20180303050328/https://www.fierceceo.com/growth-innovation/methuselah-health-ceo-david-grainger-out-to-aid-longevity. dead.
  3. News: Methuselah Health Using Protein PTM Analysis to Tackle Age-Related Diseases. GenomeWeb. February 28, 2018.
  4. News: Index Ventures Raises $442 Million in New Fund. New York Times Dealbook. June 17, 2012.
  5. Web site: Forbes.com Contributor column: David Grainger . Forbes.
  6. Web site: BusinessWeek profile: David Grainger . https://archive.today/20140118191729/http://investing.businessweek.com/research/stocks/private/person.asp?personId=28066856&privcapId=28033081&previousCapId=241734400&previousTitle=XO1+Ltd . dead . 18 January 2014 .
  7. News: Heart Disease Breakthrough Claimed. Nature Medicine. November 25, 2002.
  8. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC . Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice . Nature . 370 . 6489 . 460–2 . 1994 . 8047165 . 10.1038/370460a0 . 1994Natur.370..460G . 4318812 .
  9. 10.1016/j.cardiores.2007.02.022. 17382916. TGF-β and atherosclerosis in man. 2007. Grainger . David . Cardiovascular Research. 74 . 2. 213–22. free.
  10. Grainger DJ . Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis . Arterioscler. Thromb. Vasc. Biol. . 24 . 3 . 399–404 . 2005 . 14699019 . 10.1161/01.ATV.0000114567.76772.33 . free .
  11. News: Index Ventures backs novel anticoagulant. Mednous. June 17, 2013.
  12. News: Cambridge merger creates Pronostics. Biotech Business week. August 7, 2006.
  13. News: Boehringer Ingelheim acquires Funxional products. thepharmaletter. July 24, 2012.
  14. News: Revolutionary Coronary Test Ends Heartache for Patients and NHS. BusinessWeekly. January 31, 2007.
  15. News: Boehringer buys PhII respiratory drug program. FierceBiotech. July 23, 2012.
  16. News: Is Big Pharma Learning from Its Late-Stage R&D Setbacks?. Forbes.com. June 7, 2013.
  17. News: To Save Pharma R&D, David Grainger Says Drug Developers Must Think Like CEOs Of Lean Startups. Forbes.com . December 14, 2013.
  18. News: XO1 Cracks Coagulation Conundrum, Raises $11M. BioWorld News. June 16, 2013.
  19. News: XO1 Raises $11M From Index Ventures to Develop Anticoagulant Drug. Dow Jones. June 17, 2013.
  20. News: Index Ventures Invests $11 Million on Clot-Busting Drug. Bloomberg News. June 16, 2013.
  21. News: Venture capitalists ride biotech wave one drug at a time . Reuters. April 10, 2015.
  22. News: J&J and GSK join Medicxi's European life sciences push . FT . February 2, 2016.
  23. Web site: Google Scholar search: David J. Grainger .
  24. 10.1126/science.8503012 . Proliferation of human smooth muscle cells promoted by lipoprotein(a) . 1993 . Grainger . D.J. . Science . 260 . 5114. 1655–1658 . 8503012 . 1993Sci...260.1655G .
  25. 10.1038/nm1202-802 . Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. 2002. Brindle. Joanne. Nature Medicine. 8. 12. 1439–1444. 12447357. 8676147.
  26. Web site: DrugBaron site.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "David Grainger".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.